Perspective Therapeutics to Participate in Upcoming November Conferences

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX) said senior leadership will attend investor meetings at two November 2025 conferences.

Meetings include one-on-one meetings at the Truist Securities BioPharma Symposium on Thursday, November 6, 2025 in New York, and a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 from 4:15–4:50 p.m. ET in Palm Beach, Florida.

SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

Truist Securities BioPharma Symposium – 1x1 only
Date: Thursday, November 6, 2025
Location: New York, NY

UBS Global Healthcare Conference – Fireside Chat
Date: Tuesday, November 11, 2025
Time: 4:15- 4:50 p.m. ET
Location: Palm Beach, FL

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the ability of the Company's proprietary technology that utilizes the alpha-emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company’s prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product candidate finishing facilities, enabled by its proprietary ²¹²Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com

FAQ

When will Perspective Therapeutics (CATX) attend the Truist Securities BioPharma Symposium?

Perspective will hold one-on-one investor meetings at the Truist event on Thursday, November 6, 2025 in New York.

What time is Perspective Therapeutics (CATX) scheduled for the UBS Global Healthcare Conference fireside chat?

The fireside chat is scheduled for Tuesday, November 11, 2025, 4:15–4:50 p.m. ET in Palm Beach, FL.

Will Perspective Therapeutics (CATX) be available for one-on-one investor meetings at the UBS conference?

The announcement lists one-on-one meetings at the Truist symposium; it specifies a fireside chat at UBS but does not list one-on-one meetings there.

How can investors request a meeting with Perspective Therapeutics (CATX) at the November conferences?

Investors should contact the company or their investor relations representative to request one-on-one meetings; the announcement confirms senior leadership availability.

Which executives from Perspective Therapeutics (CATX) will attend the November 2025 conferences?

The announcement states members of senior leadership will participate but does not name specific executives.